AAAAAA

   
Results: 1-25 | 26-31
Results: 1-25/31
CHEMORADIOTHERAPY OF HEAD AND NECK STAGE IV SQUAMOUS-CELL CARCINOMA WITH CONCOMITANT CHEMOTHERAPY DELIVERED EACH DAY OF RADIOTHERAPY
Authors: BAILLET F DESSARDDIANA B DIANA C SIMON JM MAZERON JJ PIERGA JY DENDALE R
Citation: F. Baillet et al., CHEMORADIOTHERAPY OF HEAD AND NECK STAGE IV SQUAMOUS-CELL CARCINOMA WITH CONCOMITANT CHEMOTHERAPY DELIVERED EACH DAY OF RADIOTHERAPY, Journal de chimie physique et de physico-chimie biologique, 95(4), 1998, pp. 662-666
TIMING OF COMBINED CHEMORADIOTHERAPY IN THE CONSERVATIVE TREATMENT OFLOCALLY ADVANCED BREAST-CANCER (LABC)
Authors: PIERGA JY CAMPANA F LAGUERRE B PALANGIE T FOURQUET A ASSELAIN B DIERAS V BEUZEBOC P DORVAL T SCHOLL S POUILLART P
Citation: Jy. Pierga et al., TIMING OF COMBINED CHEMORADIOTHERAPY IN THE CONSERVATIVE TREATMENT OFLOCALLY ADVANCED BREAST-CANCER (LABC), European journal of cancer, 34, 1998, pp. 42-42
IS PRIMARY CHEMOTHERAPY USEFUL IN ALL PATIENTS
Authors: SCHOLL S BEUZEBOC P ASSELAIN B PIERGA JY POUILLART P
Citation: S. Scholl et al., IS PRIMARY CHEMOTHERAPY USEFUL IN ALL PATIENTS, European journal of cancer, 34, 1998, pp. 22-22
PROGNOSTIC-SIGNIFICANCE OF VASCULAR TUMOR EMBOLI IN 1518 BREAST-CARCINOMA PATIENTS WITH SMALL TUMOR SIZE (LESS-THAN-OR-EQUAL-TO-3 CM)
Authors: PIERGA JY VINCENTSALOMON A COUSINEAU M ZAFRANI B ASSELAIN B DIERAS V SASTREGARAU X POUILLART P
Citation: Jy. Pierga et al., PROGNOSTIC-SIGNIFICANCE OF VASCULAR TUMOR EMBOLI IN 1518 BREAST-CARCINOMA PATIENTS WITH SMALL TUMOR SIZE (LESS-THAN-OR-EQUAL-TO-3 CM), European journal of cancer, 34, 1998, pp. 31-31
INITIAL VERSUS DELAYED RADIOTHERAPY COMBINED WITH CONTINUOUS 5-FLUOROURACILE (F), CYCLOPHOSPHAMIDE (C) AND DOXORUBICINE (A) IN INFLAMMATORYBREAST-CANCER (IBC)
Authors: PALANGIE T ASSELAIN B CAMPANA F BEUZEBOC P DIERAS V DORVAL T JOUVE M PIERGA JY SCHOLL S POUILLART P
Citation: T. Palangie et al., INITIAL VERSUS DELAYED RADIOTHERAPY COMBINED WITH CONTINUOUS 5-FLUOROURACILE (F), CYCLOPHOSPHAMIDE (C) AND DOXORUBICINE (A) IN INFLAMMATORYBREAST-CANCER (IBC), European journal of cancer, 34, 1998, pp. 64-64
PREDICTIVE FACTORS OF RESPONSE TO FIRST LINE CHEMOTHERAPY IN METASTATIC BREAST-CANCER (MBC)
Authors: ROBAIN M PIERGA JY LAURENCE V JOUVE M DIERAS V BEUZEBOC P PALANGIE T DORVAL T SCHOLL S EXTRA JM ASSELAIN B POUILLART P
Citation: M. Robain et al., PREDICTIVE FACTORS OF RESPONSE TO FIRST LINE CHEMOTHERAPY IN METASTATIC BREAST-CANCER (MBC), Annals of oncology, 9, 1998, pp. 71-71
RANDOMIZED TRIAL COMPARING PROTRACTED INFUSION OF 5-FLUOROURACIL WITHWEEKLY DOXORUBICIN AND CYCLOPHOSPHAMIDE WITH A MONTHLY BOLUS FAC REGIMEN IN METASTATIC BREAST-CARCINOMA (SPM90)
Authors: PIERGA JY JOUVE M ASSELAIN B LIVARTOWSKI A BEUZEBOC P DIERAS V SCHOLL S DORVAL T PALANGIE T GARCIAGIRALT E POUILLART P
Citation: Jy. Pierga et al., RANDOMIZED TRIAL COMPARING PROTRACTED INFUSION OF 5-FLUOROURACIL WITHWEEKLY DOXORUBICIN AND CYCLOPHOSPHAMIDE WITH A MONTHLY BOLUS FAC REGIMEN IN METASTATIC BREAST-CARCINOMA (SPM90), British Journal of Cancer, 77(9), 1998, pp. 1474-1479
OVEREXPRESSION OF PDGF RECEPTOR-BETA IN DERMAL FIBROBLASTS OF LYMPHANGITIC POST RADIOTHERAPY RELAPSES OF BREAST-CARCINOMA
Authors: PIERGA JY BENYAHIA B CAMMILLERI S PALANGIE T BEUZEBOC P POUILLART P MAGDELENAT H
Citation: Jy. Pierga et al., OVEREXPRESSION OF PDGF RECEPTOR-BETA IN DERMAL FIBROBLASTS OF LYMPHANGITIC POST RADIOTHERAPY RELAPSES OF BREAST-CARCINOMA, Breast, 6(4), 1997, pp. 206-211
RESPONSE TO CHEMOTHERAPY IS THE FIRST PROGNOSTIC FACTOR IN METASTATICBREAST-CANCER
Authors: PIERGA JY JOUVE M ASSELAIN B DIERAS V BEUZEBOC P PALANGIE T DORVAL T GARCIAGIRALT E SCHOLL S POUILLART P
Citation: Jy. Pierga et al., RESPONSE TO CHEMOTHERAPY IS THE FIRST PROGNOSTIC FACTOR IN METASTATICBREAST-CANCER, European journal of cancer, 33, 1997, pp. 653-653
PHASE-II TRIAL OF DOXORUBICIN, 5-FLUOROURACIL, ETOPOSIDE, AND CISPLATIN IN ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA
Authors: PIERGA JY DIERAS V BEUZEBOC P DORVAL T PALANGIE T JOUVE M SCHOLL SM GARCIAGIRALT E POUILLART P
Citation: Jy. Pierga et al., PHASE-II TRIAL OF DOXORUBICIN, 5-FLUOROURACIL, ETOPOSIDE, AND CISPLATIN IN ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA, Gynecologic oncology, 66(2), 1997, pp. 246-249
TREATMENT OF MALIGNANT GLIOMAS (MG) IN THE ELDERLY (GREATER-THAN-OR-EQUAL-TO-70 YEARS)
Authors: PIERGA JY HOANGXUAN K SIMON JM CORNU P BAILLET F POISSON M MAZERON JJ DELATTRE JY MARTIN N
Citation: Jy. Pierga et al., TREATMENT OF MALIGNANT GLIOMAS (MG) IN THE ELDERLY (GREATER-THAN-OR-EQUAL-TO-70 YEARS), Neurology, 48(3), 1997, pp. 1004-1004
PLASMINOGEN-ACTIVATOR INHIBITOR-1 (PAI-1) IS NOT RELATED TO RESPONSE TO NEOADJUVANT CHEMOTHERAPY IN BREAST-CANCER
Authors: PIERGA JY LAINEBIDRON C BEUZEBOC P DECREMOUX P POUILLART P MAGDELENAT H
Citation: Jy. Pierga et al., PLASMINOGEN-ACTIVATOR INHIBITOR-1 (PAI-1) IS NOT RELATED TO RESPONSE TO NEOADJUVANT CHEMOTHERAPY IN BREAST-CANCER, British Journal of Cancer, 76(4), 1997, pp. 537-540
BRCA1 SEQUENCE VARIATIONS IN 160 INDIVIDUALS REFERRED TO A BREAST OVARIAN FAMILY CANCER CLINIC/
Authors: STOPPALYONNET D LAURENTPUIG P ESSIOUX L PAGES S ITHIER G LIGOT L FOURQUET A SALMON RJ CLOUGH KB POUILLART P ALAPETITE C ALEPEE B KLIJANIENKO J ASSELAIN B BEUZEBOC P BOURGEOIS D BOURGEOIS H BOURSTYN E BRUNIN F CAMPANA F CHAUVEINC F COSSET JM DECREMOUX P DELAROCHEFORDIERE A DELATTRE C DEMARGERIE V DESTGAUDENS AB DIERAS V DORVAL T DUBRAY B DURAND JC FALCOU MC FITOUSSI F GARCIAGIRALT E GIRAUD P GAUTIER C GUGLIELMINA JN HAMELIN JP HOFFMAN H JAULERRY C JOUVE M LABETA C LEGALL M MAGDELENAT H MEUNIER M MOSSERI V NGUYEN TT NATALI JC NEUENSCHWANDER S NOS C OLIVIER L PALANGIE T PIERGA JY PONTVERT D ROGE P SASTREGAREAU X SCHLIENGER P SCHOLL S SELINGER R THIBAULT F THIS P TROPHILME D VALIDIRE P VIELH P VILCOQ JR VINCENTSALOMON A VOILLEMOT N ZAFRANI B BONAITIPELLIE C THOMAS G
Citation: D. Stoppalyonnet et al., BRCA1 SEQUENCE VARIATIONS IN 160 INDIVIDUALS REFERRED TO A BREAST OVARIAN FAMILY CANCER CLINIC/, American journal of human genetics, 60(5), 1997, pp. 1021-1030
SEVERE 5-FLUOROURACIL TOXICITY POSSIBLY SECONDARY TO DIHYDROPYRIMIDINE DEHYDROGENASE-DEFICIENCY IN A BREAST-CANCER PATIENT WITH OSTEOGENESIS IMPERFECTA
Authors: BEUZEBOC P PIERGA JY LYONNET DS ETIENNE MC MILANO G POUILLART P
Citation: P. Beuzeboc et al., SEVERE 5-FLUOROURACIL TOXICITY POSSIBLY SECONDARY TO DIHYDROPYRIMIDINE DEHYDROGENASE-DEFICIENCY IN A BREAST-CANCER PATIENT WITH OSTEOGENESIS IMPERFECTA, European journal of cancer, 32A(2), 1996, pp. 369-370
EFFICACY AND TOLERANCE OF VINORELBINE AND FLUOROURACIL COMBINATION ASFIRST-LINE CHEMOTHERAPY OF ADVANCED BREAST-CANCER - RESULTS OF A PHASE-II STUDY USING A SEQUENTIAL GROUP METHOD
Authors: DIERAS V EXTRA JM BELLISSANT E ESPIE M MORVAN F PIERGA JY MIGNOT L TRESCA P MARTY M
Citation: V. Dieras et al., EFFICACY AND TOLERANCE OF VINORELBINE AND FLUOROURACIL COMBINATION ASFIRST-LINE CHEMOTHERAPY OF ADVANCED BREAST-CANCER - RESULTS OF A PHASE-II STUDY USING A SEQUENTIAL GROUP METHOD, Journal of clinical oncology, 14(12), 1996, pp. 3097-3104
LONG-TERM PROGNOSTIC VALUE OF GROWTH FRACTION DETERMINATION BY KI-67 IMMUNOSTAINING IN PRIMARY OPERABLE BREAST-CANCER
Authors: PIERGA JY LEROYER A VIEHL P MOSSERI V CHEVILLARD S MAGDELENAT H
Citation: Jy. Pierga et al., LONG-TERM PROGNOSTIC VALUE OF GROWTH FRACTION DETERMINATION BY KI-67 IMMUNOSTAINING IN PRIMARY OPERABLE BREAST-CANCER, Breast cancer research and treatment, 37(1), 1996, pp. 57-64
TREATMENT OF ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA WITH COMBINATION OF ETOPOSIDE, CISPLATIN, AND 5-FLUOROURACIL - A PHASE-II STUDY
Authors: PIERGA JY DIERAS V PARAISO D DORVAL T PALANGIE T BEUZEBOC P JOUVE M SCHOLL SM GARCIAGIRALT E POUILLART P
Citation: Jy. Pierga et al., TREATMENT OF ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA WITH COMBINATION OF ETOPOSIDE, CISPLATIN, AND 5-FLUOROURACIL - A PHASE-II STUDY, Gynecologic oncology, 60(1), 1996, pp. 59-63
SEVERE 5-FLUOROURACIL TOXICITY IN A BREAS T-CANCER PATIENT WITH CONCURRENT OSTEOGENESIS IMPERFECTA AND DEHYDROGENASE-DEFICIENCY
Authors: BEUZEBOC P PIERGA JY LYONNET DS COUTURIER J POUILLART P
Citation: P. Beuzeboc et al., SEVERE 5-FLUOROURACIL TOXICITY IN A BREAS T-CANCER PATIENT WITH CONCURRENT OSTEOGENESIS IMPERFECTA AND DEHYDROGENASE-DEFICIENCY, Bulletin du cancer, 83(4), 1996, pp. 324-327
INDUCTIBILITY OF MDR1 GENE-EXPRESSION, S- PHASE AND RESPONSE TO NEOADJUVANT CHEMOTHERAPY
Authors: MAGDELENAT H CHEVILLARD S BEUZEBOC P PIERGA JY VIELH P POUILLART P
Citation: H. Magdelenat et al., INDUCTIBILITY OF MDR1 GENE-EXPRESSION, S- PHASE AND RESPONSE TO NEOADJUVANT CHEMOTHERAPY, Bulletin du cancer, 83(12), 1996, pp. 1037-1037
IMAGING AND BIODISTRIBUTION OF I-125 TYRAMINE OLIGONUCLEOTIDE IN NUDE-MICE BEARING HUMAN BREAST-TUMOR - PRELIMINARY-REPORT
Authors: CAMMILLERI S PERDEREAU B BRIXY F PIERGA JY BENYAHIA B CHYPRE C MAGDELENAT H
Citation: S. Cammilleri et al., IMAGING AND BIODISTRIBUTION OF I-125 TYRAMINE OLIGONUCLEOTIDE IN NUDE-MICE BEARING HUMAN BREAST-TUMOR - PRELIMINARY-REPORT, Bulletin du cancer, 83(1), 1996, pp. 23-26
THE ROLE OF RADIATION-THERAPY IN THE TREATMENT OF TYMPANO-JUGULAR CHEMODECTOMAS
Authors: PIERGA JY DESSARDDIANA B RONCHIN P DIANA C MAZERON JJ BAILLET F
Citation: Jy. Pierga et al., THE ROLE OF RADIATION-THERAPY IN THE TREATMENT OF TYMPANO-JUGULAR CHEMODECTOMAS, European journal of cancer, 31A, 1995, pp. 174-174
BREAST-TUMOR RESPONSE TO PRIMARY CHEMOTHERAPY PREDICTS LOCAL AND DISTANT CONTROL AS WELL AS SURVIVAL
Authors: SCHOLL SM PIERGA JY ASSELAIN B BEUZEBOC P DORVAL T GARCIAGIRALT E JOUVE M PALANGIE T REMVIKOS Y DURAND JC FOURQUET A POUILLART P
Citation: Sm. Scholl et al., BREAST-TUMOR RESPONSE TO PRIMARY CHEMOTHERAPY PREDICTS LOCAL AND DISTANT CONTROL AS WELL AS SURVIVAL, European journal of cancer, 31A(12), 1995, pp. 1969-1975
CHEMOTHERAPY IN METASTATIC ENDOMETRIAL CA RCINOMA - REVIEW OF THE LITERATURE
Authors: PIERGA JY DIERAS V PARAISO D POUILLART P
Citation: Jy. Pierga et al., CHEMOTHERAPY IN METASTATIC ENDOMETRIAL CA RCINOMA - REVIEW OF THE LITERATURE, Bulletin du cancer, 82(12), 1995, pp. 1005-1018
NEOADJUVANT VERSUS ADJUVANT CHEMOTHERAPY IN PREMENOPAUSAL PATIENTS WITH TUMORS CONSIDERED TOO LARGE FOR BREAST-CONSERVING SURGERY - PRELIMINARY-RESULTS OF A RANDOMIZED TRIAL - S6
Authors: SCHOLL SM FOURQUET A ASSELAIN B PIERGA JY VILCOQ JR DURAND JC DORVAL T PALANGIE T JOUVE M BEUZEBOC P GARCIOGIRALT E SALMON RJ DELAROCHEFORDIERE A CAMPANA F POUILLART P
Citation: Sm. Scholl et al., NEOADJUVANT VERSUS ADJUVANT CHEMOTHERAPY IN PREMENOPAUSAL PATIENTS WITH TUMORS CONSIDERED TOO LARGE FOR BREAST-CONSERVING SURGERY - PRELIMINARY-RESULTS OF A RANDOMIZED TRIAL - S6, European journal of cancer, 30A(5), 1994, pp. 645-652
SECONDARY SOLID MALIGNANT-TUMORS OCCURRING AFTER BONE-MARROW TRANSPLANTATION FOR SEVERE APLASTIC-ANEMIA GIVEN THORACOABDOMINAL IRRADIATION
Authors: PIERGA JY SOCIE G GLUCKMAN E DEVERGIE A HENRYAMAR M BRIDIER A GIRINSKY T NGUYEN J COSSET JM
Citation: Jy. Pierga et al., SECONDARY SOLID MALIGNANT-TUMORS OCCURRING AFTER BONE-MARROW TRANSPLANTATION FOR SEVERE APLASTIC-ANEMIA GIVEN THORACOABDOMINAL IRRADIATION, Radiotherapy and oncology, 30(1), 1994, pp. 55-58
Risultati: 1-25 | 26-31